COMBINED MODALITY TREATMENT INCLUDING METHOTREXATE-BASED CHEMOTHERAPY FOR PRIMARY CEREBRAL NERVOUS SYSTEM LYMPHOMA: A SINGLE INSTITUTION EXPERIENCE
Chemotherapy including high-dose methotrexate (HD-MTX), with or without radiotherapy, is standard treatment for primary cerebral nervous system lymphoma (PCNSL). It remains controversial whether addition of other drugs will add to therapeutic efficacy. We report here on 41 patients with PCNSL treate...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2009-12-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.mjhid.org/index.php/mjhid/article/view/138 |
| _version_ | 1826908743134085120 |
|---|---|
| author | Stefan Hohaus Luciana Teofili Mario Balducci Stefania Manfrida Angelo Pompucci Francesco D'Alo' Giuseppina Massini Luigi Maria Larocca Roberto Marra Sergio Storti |
| author_facet | Stefan Hohaus Luciana Teofili Mario Balducci Stefania Manfrida Angelo Pompucci Francesco D'Alo' Giuseppina Massini Luigi Maria Larocca Roberto Marra Sergio Storti |
| author_sort | Stefan Hohaus |
| collection | DOAJ |
| description | Chemotherapy including high-dose methotrexate (HD-MTX), with or without radiotherapy, is standard treatment for primary cerebral nervous system lymphoma (PCNSL). It remains controversial whether addition of other drugs will add to therapeutic efficacy. We report here on 41 patients with PCNSL treated using a combined treatment modality, including HD-MTX (3.5 g/m2 for 2 cycles) prior to whole brain radiotherapy (WBRT). In 22 patients, the chemotherapy was intensified by adding high-dose cytosine arabinoside (HD-AraC) (2g/m2 for 4 doses for 2 cycles). Complete remission was obtained in 23 of 34 assessable patients (67%), and overall and disease-free survival rates were 24% and 46%, respectively, without differences between treatment groups. The addition of HD-AraC was complicated by severe infections in 17/22 (77%) patients, resulting in 3 toxic deaths. Our study indicates that addition of HD-AraC may not improve clinical outcome in PCNSL, while it increases toxicity. More targeted and less toxic therapies are warranted. |
| first_indexed | 2024-12-20T21:52:26Z |
| format | Article |
| id | doaj.art-956b9cd0f4cf46a89fed56f5c5bca01f |
| institution | Directory Open Access Journal |
| issn | 2035-3006 |
| language | English |
| last_indexed | 2025-02-17T09:28:44Z |
| publishDate | 2009-12-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Mediterranean Journal of Hematology and Infectious Diseases |
| spelling | doaj.art-956b9cd0f4cf46a89fed56f5c5bca01f2025-01-02T11:15:08ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062009-12-0112e2009020e200902010.4084/mjhid.2009.02032COMBINED MODALITY TREATMENT INCLUDING METHOTREXATE-BASED CHEMOTHERAPY FOR PRIMARY CEREBRAL NERVOUS SYSTEM LYMPHOMA: A SINGLE INSTITUTION EXPERIENCEStefan Hohaus0Luciana TeofiliMario BalducciStefania ManfridaAngelo PompucciFrancesco D'Alo'Giuseppina MassiniLuigi Maria LaroccaRoberto MarraSergio StortiCatholic UniversityChemotherapy including high-dose methotrexate (HD-MTX), with or without radiotherapy, is standard treatment for primary cerebral nervous system lymphoma (PCNSL). It remains controversial whether addition of other drugs will add to therapeutic efficacy. We report here on 41 patients with PCNSL treated using a combined treatment modality, including HD-MTX (3.5 g/m2 for 2 cycles) prior to whole brain radiotherapy (WBRT). In 22 patients, the chemotherapy was intensified by adding high-dose cytosine arabinoside (HD-AraC) (2g/m2 for 4 doses for 2 cycles). Complete remission was obtained in 23 of 34 assessable patients (67%), and overall and disease-free survival rates were 24% and 46%, respectively, without differences between treatment groups. The addition of HD-AraC was complicated by severe infections in 17/22 (77%) patients, resulting in 3 toxic deaths. Our study indicates that addition of HD-AraC may not improve clinical outcome in PCNSL, while it increases toxicity. More targeted and less toxic therapies are warranted.http://www.mjhid.org/index.php/mjhid/article/view/138Lymphoma |
| spellingShingle | Stefan Hohaus Luciana Teofili Mario Balducci Stefania Manfrida Angelo Pompucci Francesco D'Alo' Giuseppina Massini Luigi Maria Larocca Roberto Marra Sergio Storti COMBINED MODALITY TREATMENT INCLUDING METHOTREXATE-BASED CHEMOTHERAPY FOR PRIMARY CEREBRAL NERVOUS SYSTEM LYMPHOMA: A SINGLE INSTITUTION EXPERIENCE Mediterranean Journal of Hematology and Infectious Diseases Lymphoma |
| title | COMBINED MODALITY TREATMENT INCLUDING METHOTREXATE-BASED CHEMOTHERAPY FOR PRIMARY CEREBRAL NERVOUS SYSTEM LYMPHOMA: A SINGLE INSTITUTION EXPERIENCE |
| title_full | COMBINED MODALITY TREATMENT INCLUDING METHOTREXATE-BASED CHEMOTHERAPY FOR PRIMARY CEREBRAL NERVOUS SYSTEM LYMPHOMA: A SINGLE INSTITUTION EXPERIENCE |
| title_fullStr | COMBINED MODALITY TREATMENT INCLUDING METHOTREXATE-BASED CHEMOTHERAPY FOR PRIMARY CEREBRAL NERVOUS SYSTEM LYMPHOMA: A SINGLE INSTITUTION EXPERIENCE |
| title_full_unstemmed | COMBINED MODALITY TREATMENT INCLUDING METHOTREXATE-BASED CHEMOTHERAPY FOR PRIMARY CEREBRAL NERVOUS SYSTEM LYMPHOMA: A SINGLE INSTITUTION EXPERIENCE |
| title_short | COMBINED MODALITY TREATMENT INCLUDING METHOTREXATE-BASED CHEMOTHERAPY FOR PRIMARY CEREBRAL NERVOUS SYSTEM LYMPHOMA: A SINGLE INSTITUTION EXPERIENCE |
| title_sort | combined modality treatment including methotrexate based chemotherapy for primary cerebral nervous system lymphoma a single institution experience |
| topic | Lymphoma |
| url | http://www.mjhid.org/index.php/mjhid/article/view/138 |
| work_keys_str_mv | AT stefanhohaus combinedmodalitytreatmentincludingmethotrexatebasedchemotherapyforprimarycerebralnervoussystemlymphomaasingleinstitutionexperience AT lucianateofili combinedmodalitytreatmentincludingmethotrexatebasedchemotherapyforprimarycerebralnervoussystemlymphomaasingleinstitutionexperience AT mariobalducci combinedmodalitytreatmentincludingmethotrexatebasedchemotherapyforprimarycerebralnervoussystemlymphomaasingleinstitutionexperience AT stefaniamanfrida combinedmodalitytreatmentincludingmethotrexatebasedchemotherapyforprimarycerebralnervoussystemlymphomaasingleinstitutionexperience AT angelopompucci combinedmodalitytreatmentincludingmethotrexatebasedchemotherapyforprimarycerebralnervoussystemlymphomaasingleinstitutionexperience AT francescodalo combinedmodalitytreatmentincludingmethotrexatebasedchemotherapyforprimarycerebralnervoussystemlymphomaasingleinstitutionexperience AT giuseppinamassini combinedmodalitytreatmentincludingmethotrexatebasedchemotherapyforprimarycerebralnervoussystemlymphomaasingleinstitutionexperience AT luigimarialarocca combinedmodalitytreatmentincludingmethotrexatebasedchemotherapyforprimarycerebralnervoussystemlymphomaasingleinstitutionexperience AT robertomarra combinedmodalitytreatmentincludingmethotrexatebasedchemotherapyforprimarycerebralnervoussystemlymphomaasingleinstitutionexperience AT sergiostorti combinedmodalitytreatmentincludingmethotrexatebasedchemotherapyforprimarycerebralnervoussystemlymphomaasingleinstitutionexperience |